Biopharma licensing and M&A trends in the 21st-century landscape

Abstract

The declining in-house R&D productivity has compelled the biopharmaceutical firms to supplement their innovation pipelines with well-managed licensing or acquisition deals. The reliance on licensed products and acquired technologies continues to increase across the industry to support pipeline expansion and technological diversification. In this article, Licensing and M&A trends across the biopharmaceutical industry are explored by examining the partnering activities of major biopharmaceutical companies and analyzing the trends in the business development transactions of the biotechnology companies worldwide. The information has been extracted from public and proprietary sources such as company annual reports, Industry reports and press releases from biopharmaceutical companies. The transactions data and partnership information has been analyzed over a contiguous twenty-year time period of 2000–2020 to understand the change in strategic focus in dealmaking and trends over the past two decades.

https://doi.org/10.5912/jcb943
Requires Subscription or Fee PDF

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.